Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

For a one-off $5 fee you can claim your username before someone else does and get a behind the scenes look at the new Digg as ...

Antiphospholipid Antibody Syndrome APS is an autoimmune condition where the immune system of the body mistakenly forms ...

I have written before that there comes a time in the life of an individual when they cease being private folk but subjects of intense public interest. They become symbols and representatives of entire ...

The financial terms of the deal were not disclosed, but TigaTx will become a wholly owned subsidiary of Epsilogen as part of ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

We recently got a chance to chat with Jun Shen Chia, the Global Expansion lead of Xbox in Southeast Asia, Taiwan, and Hong ...

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across ...